NCT06176339

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Breast cancer, a leading cause of cancer-related mortality in women worldwide, has spurred the investigation of novel therapeutic approaches. Pentoxifylline (PTX), a synthetic methylxanthine derivative, has shown promise in preclinical studies when combined with conventional anticancer drugs. This study aims to assess PTX's impact when added to neoadjuvant chemotherapy protocols in breast cancer patients, with the goal of improving treatment outcomes and reducing associated toxicities.

Conditions

• Breast Cancer Female

Interventions

Type	Name	Description
DRUG	Pentoxifylline Oral Tablet	Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
DRUG	Placebo	Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.

Timeline

• Start date: 2023-12-15
• Primary completion: 2024-08-30
• Completion: 2024-09-30
• First posted: 2023-12-19
• Last updated: 2024-03-15

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study